News and Comments

ImmunoGen: No Exaggeration.

Prohost Biotech - Thursday, April 07, 2011

NO. It was not exaggerated, nor sophisticated what we wrote time and time again about the unparalleled safety and efficacy of the ImmunoGen’s Targeted Antibody Payload (TAP). It is no exaggeration announcing our conviction that cancer products based on Immunogen’s TAP   technology will generate billions of dollars in revenues. What we talked about has, indeed, become today’s great news.

After studying results from the first randomized trial aimed at assessing (T-DM1), Roche stated that patients treated with T-DM1 had a significant improvement in progression-free survival compared with patients treated with Herceptin® (trastuzumab) plus chemotherapy (docetaxel) in the Phase II trial compared TDM-1. The detailed findings from this randomized, 137-patient trial are being submitted for presentation at a future medical conference. Good news? Of course it is, especially for those who expected it and acted upon their convictions Expert’s positive expectations about ImmunoGen’s drugs started to rise since early results were released followed by the recent results presented at the 35th Congress of the European Society of Medical Oncology (ESMO) where very favorable preliminary data were reported. The only missing data from the study at the time were those on progression-free survival.

Well! Here we are. The data have been disclosed and guess what? In addition to the unparalleled safety of the T-DM1, this drug had significantly improved the progression-free survival compared with patients treated with what is being considered the best agents for first-line treatment of HER2-positive metastatic breast cancer. These agents included Herceptin® (trastuzumab), the multibillion dollar-generating drug developed by Roche, which, we believe, T-DM1 will soon replace, plus chemotherapy (docetaxel) in the Phase II trial for first-line treatment.

We are looking forward to learn more details about the data when it would be reported at an upcoming conference, as promised by the firms. What we really wish to see, however, is early approval of this drug so it could save lives of desperate patients who have no other treatment option to hope about.

In recent article, we reported news that the Program Committee of the 102nd Annual Meeting of the American Association for Cancer Research (AACR) designated ImmunoGen’s (IMGN) new cancer drug IMGN853 poster presentation “Highly Rated.” ImmunoGen made nine presentations at the AACR meeting were more evidence-based facts about its technology and products were revealed so analysts can assess this firm in a fair way. To read this article click: ImmunoGen: Steadfast Determination to Conquer Cancer

This is only the tip of the iceberg. The current extremely promising new will repeat in each and every drug developed through Immunogen’s TAP technology. These products are growing and advancing in clinical trials, covering many cancers. We are confident that ImmunoGen will continue to expand its pipeline to cover most cancers. We are sure that it will continue to further improve on the technology and the products the drugs. Most ImmunoGen drugs, we speculate, will outperform conventional drugs and many will end up approved as first-line treatments, in addition to treatment of advanced metastasized cancers.

Again we say: We Long this firm

Comments
Post has no comments.
Post a Comment




Captcha Image

Trackback Link
http://www.prohostbiotech.com/BlogRetrieve.aspx?BlogID=8883&PostID=221889&A=Trackback
Trackbacks
Post has no trackbacks.

Recent News_and_Comments


Archive


Tags